148 related articles for article (PubMed ID: 38716804)
21. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
22. Aberrant gene methylation in non-neoplastic mucosa as a predictive marker of ulcerative colitis-associated CRC.
Scarpa M; Scarpa M; Castagliuolo I; Erroi F; Kotsafti A; Basato S; Brun P; D'Incà R; Rugge M; Angriman I; Castoro C
Oncotarget; 2016 Mar; 7(9):10322-31. PubMed ID: 26862732
[TBL] [Abstract][Full Text] [Related]
23. Altered regulation of DNA ligase IV activity by aberrant promoter DNA methylation and gene amplification in colorectal cancer.
Kuhmann C; Li C; Kloor M; Salou M; Weigel C; Schmidt CR; Ng LW; Tsui WW; Leung SY; Yuen ST; Becker N; Weichenhan D; Plass C; Schmezer P; Chan TL; Popanda O
Hum Mol Genet; 2014 Apr; 23(8):2043-54. PubMed ID: 24282031
[TBL] [Abstract][Full Text] [Related]
24. Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy.
Pfütze K; Benner A; Hoffmeister M; Jansen L; Yang R; Bläker H; Herpel E; Ulrich A; Ulrich CM; Chang-Claude J; Brenner H; Burwinkel B
Genomics; 2015 Dec; 106(6):348-54. PubMed ID: 26453961
[TBL] [Abstract][Full Text] [Related]
25. Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.
Heitzer E; Artl M; Filipits M; Resel M; Graf R; Weißenbacher B; Lax S; Gnant M; Wrba F; Greil R; Dietze O; Hofbauer F; Böhm G; Höfler G; Samonigg H; Schaberl-Moser R; Balic M; Dandachi N
Mod Pathol; 2014 Jun; 27(6):906-15. PubMed ID: 24309322
[TBL] [Abstract][Full Text] [Related]
26. Promoter Hypermethylation of the Eyes Absent 4 Gene is a Tumor-Specific Epigenetic Biomarker in Iranian Colorectal Cancer Patients.
Barati Bagerabad M; Tavakolian S; Abbaszadegan MR; Kerachian MA
Acta Med Iran; 2018 Jan; 56(1):21-27. PubMed ID: 29436791
[TBL] [Abstract][Full Text] [Related]
27. CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients.
Harder J; Engelstaedter V; Usadel H; Lassmann S; Werner M; Baier P; Otto F; Varbanova M; Schaeffner E; Olschewski M; Blum HE; Opitz OG
Br J Cancer; 2009 Jan; 100(2):360-5. PubMed ID: 19142184
[TBL] [Abstract][Full Text] [Related]
28. Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer.
Tanaka M; Chang P; Li Y; Li D; Overman M; Maru DM; Sethi S; Phillips J; Bland GL; Abbruzzese JL; Eng C
Clin Cancer Res; 2011 Jul; 17(13):4531-40. PubMed ID: 21551253
[TBL] [Abstract][Full Text] [Related]
29. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.
Liu M; Peng Y; Wang X; Guo Q; Shen S; Li G
BMC Cancer; 2010 Apr; 10():160. PubMed ID: 20423473
[TBL] [Abstract][Full Text] [Related]
30. IGFBP3 gene promoter methylation analysis and its association with clinicopathological characteristics of colorectal carcinoma.
Kumar A; Singh P; Pandey A; Gosipatala SB
Mol Biol Rep; 2020 Sep; 47(9):6919-6927. PubMed ID: 32929656
[TBL] [Abstract][Full Text] [Related]
31. Novel methylation gene panel in adjacent normal tissues predicts poor prognosis of colorectal cancer in Taiwan.
Hsu CH; Hsiao CW; Sun CA; Wu WC; Yang T; Hu JM; Huang CH; Liao YC; Chen CY; Lin FH; Chou YC
World J Gastroenterol; 2020 Jan; 26(2):154-167. PubMed ID: 31988582
[TBL] [Abstract][Full Text] [Related]
32. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
33. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
Ogino S; Meyerhardt JA; Irahara N; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Schaefer P; Whittom R; Hantel A; Benson AB; Goldberg RM; Bertagnolli MM; Fuchs CS; ; ; ;
Clin Cancer Res; 2009 Dec; 15(23):7322-9. PubMed ID: 19934290
[TBL] [Abstract][Full Text] [Related]
34. Prognostic relevance of an epigenetic biomarker panel in sentinel lymph nodes from colon cancer patients.
Lind GE; Guriby M; Ahlquist T; Hussain I; Jeanmougin M; Søreide K; Kørner H; Lothe RA; Nordgård O
Clin Epigenetics; 2017; 9():97. PubMed ID: 28878843
[TBL] [Abstract][Full Text] [Related]
35. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
[TBL] [Abstract][Full Text] [Related]
36. Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis.
Semaan A; Uhl B; Branchi V; Lingohr P; Bootz F; Kristiansen G; Kalff JC; Matthaei H; Pantelis D; Dietrich D
Clin Colorectal Cancer; 2018 Jun; 17(2):e385-e393. PubMed ID: 29580650
[TBL] [Abstract][Full Text] [Related]
37. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
38. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
[TBL] [Abstract][Full Text] [Related]
39. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers.
Yoshino M; Suzuki M; Tian L; Moriya Y; Hoshino H; Okamoto T; Yoshida S; Shibuya K; Yoshino I
Int J Oncol; 2009 Nov; 35(5):1201-9. PubMed ID: 19787276
[TBL] [Abstract][Full Text] [Related]
40. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
